论文部分内容阅读
本文采用随机、双盲、多中心试验比较了新的长效双氢吡啶类钙拮抗剂氨氯地平(amlodipine,简称AML)和长效β阻滞剂纳多洛尔(nadolol,简称NAD)对稳定劳力型心绞痛的长期疗效和安全性。将80例稳定劳力型心绞痛病人随机分为AML组(40例)和NAD组(40例),研究前停用一切抗心绞痛药物至少1周。所有病人在2周的单盲安慰剂期后,随机双盲接受AML2.5mg每日1次或NAD40mg每日1次。在4周的双盲期后,AML和NAD的剂量分别增至5mg和80mg每日1次。在8周的双盲期后,若仍未达到最佳疗效或无明显副作用,则AML和NAD剂量分别再增至10mg
In this study, a new long-acting dihydropyridine calcium antagonist, amlodipine (AML) and a long-acting β blocker, nadolol (NAD), were compared in a randomized, double- Long-term efficacy and safety of stable angina pectoris. Eighty patients with stable angina pectoris were randomly divided into AML group (n = 40) and NAD group (n = 40). All anti-anginal drugs were discontinued before the study for at least 1 week. All patients were randomized to double-blind AML 2.5 mg once daily or NAD 40 mg once daily after a two-week, single-blind placebo. After a four-week, double-blind period, the doses of AML and NAD were increased to 5 mg and 80 mg daily, respectively. After an eight-week, double-blind period, the dose of AML and NAD were again increased to 10 mg if the best effect or no significant side effects were still achieved